Regulatory T cells (Tregs) are one of the most important components in the immune suppressive networks in the tumor microenvironment. Tregs dampen tumor associated antigen (TAA)-specific T cell immunity and are thought to be the main obstacle tempering successful immunotherapy and active vaccination. Accumulating evidence indicates that tumor microenvironment controls the recruitment of Tregs, and Tregs interact with antigen presenting cells (APCs) and T cells to mediate immune suppression. Multiple modes of action of suppression are proposed in the literature to dissect their suppressive mechanisms. However, the cellular and molecular mechanisms controlling the survival, the phenotypic and functional integrity of Tregs in the human tumor microenvironment remain poorly understood. In this proposal we take human ovarian cancer as a typical research model to address these significant questions.
Our specific aims are:
Aim 1 is to test our hypothesis that functional CXCR4 on Tregs is induced by hypoxia in the tumor microenvironment. The HIF/CXCR4 pathway will be explored.
Aim 2 is to test our hypothesis that Tregs survive hypoxia through interacting with tumor cells in the tumor microenvironment. The CXCR4/CXCL12 pathway will be explored.
Aim 3 is to test the hypothesis that hypoxia regulates Treg functional stability and integrity in human ovarian cancer. The HIF/Notch pathway will be explored. Our proposal will provide a novel mechanism linking the HIF signaling pathway to Treg survival, phenotype and functional integrity in the human tumor microenvironment. Understanding this new molecular link and the relevance will shed significant light on human Treg biology and provide useful information for designing novel therapeutic strategies to treat patients with cancer.
It has been shown that tumor infiltrating effector T cells are positively and regulatory T cells (Tregs) are negatively associated with patient outcome in multiple human cancers. Tumor associated antigen (TAA)-specific T cell responses are induced by tumor immune therapy and vaccination in patients with cancer. However, the cellular and molecular mechanisms controlling the survival, the phenotypic and functional integrity of Tregs in the human tumor microenvironment remain poorly understood. Understanding the molecular circuitry that contributes to the maintenance and survival of Tregs in the tumor microenvironment will generate novel information on human Treg biology, and provide insight into new approaches in cancer therapy.
|Zou, Weiping; Wolchok, Jedd D; Chen, Lieping (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med 8:328rv4|
|Zhao, Ende; Maj, Tomasz; Kryczek, Ilona et al. (2016) Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol 17:95-103|
|Peng, Dongjun; Tanikawa, Takashi; Li, Wei et al. (2016) Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Res 76:3156-65|
|Wang, Weimin; Kryczek, Ilona; DostÃ¡l, LubomÃr et al. (2016) Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. Cell 165:1092-105|
|Nagarsheth, Nisha; Peng, Dongjun; Kryczek, Ilona et al. (2016) PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. Cancer Res 76:275-82|
|Peng, Dongjun; Kryczek, Ilona; Nagarsheth, Nisha et al. (2015) Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527:249-53|
|Kryczek, Ilona; Lin, Yanwei; Nagarsheth, Nisha et al. (2014) IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 40:772-84|
|Crespo, Joel; Sun, Haoyu; Welling, Theodore H et al. (2013) T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol 25:214-21|
|Cui, Tracy X; Kryczek, Ilona; Zhao, Lili et al. (2013) Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 39:611-21|
|Kryczek, Ilona; Liu, Suling; Roh, Michael et al. (2012) Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer 130:29-39|
Showing the most recent 10 out of 26 publications